Redmile Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Redmile Group’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-913,319	Closed	-$72.8M	–	78
2022 Q2	$72.8M	Buy	+913,319	New	+$86.5M	2.78%	7
2019 Q4	–	Sell	-14,700	Closed	-$400K	–	87
2019 Q3	$400K	Buy	14,700 +3,300	+29%	+$85.3K	0.01%	60
2019 Q2	$274K	Buy	+11,400	New	+$289K	0.01%	73
2018 Q3	–	Sell	-25,800	Closed	-$427K	–	101
2018 Q2	$427K	Buy	25,800 +5,800	+29%	+$88.4K	0.01%	69
2018 Q1	$284K	Hold	20,000	–	–	0.01%	61
2017 Q4	$292K	Buy	+20,000	New	+$281K	0.01%	63

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Redmile Group's HZNP Position: Q3 2022 in Review

Redmile Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 913,319 shares — an estimated $72.8M sold.

Redmile Group first reported a position in HZNP in Q4 2017 and held it in 6 quarters. The position peaked at $72.8M in Q2 2022. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Redmile Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Redmile Group sold 913,319 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $72.8M.
Redmile Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 6 quarters.
Redmile Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $72.8M in Q2 2022.
529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Redmile Group's 13F filing for Q3 2022, filed 14 Nov 2022.